263 related articles for article (PubMed ID: 35234927)
1. Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing.
O'Geen H; Tomkova M; Combs JA; Tilley EK; Segal DJ
Nucleic Acids Res; 2022 Apr; 50(6):3239-3253. PubMed ID: 35234927
[TBL] [Abstract][Full Text] [Related]
2. Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner.
O'Geen H; Bates SL; Carter SS; Nisson KA; Halmai J; Fink KD; Rhie SK; Farnham PJ; Segal DJ
Epigenetics Chromatin; 2019 May; 12(1):26. PubMed ID: 31053162
[TBL] [Abstract][Full Text] [Related]
3. dCas9-based epigenome editing suggests acquisition of histone methylation is not sufficient for target gene repression.
O'Geen H; Ren C; Nicolet CM; Perez AA; Halmai J; Le VM; Mackay JP; Farnham PJ; Segal DJ
Nucleic Acids Res; 2017 Sep; 45(17):9901-9916. PubMed ID: 28973434
[TBL] [Abstract][Full Text] [Related]
4. Efficient Targeted DNA Methylation with dCas9-Coupled DNMT3A-DNMT3L Methyltransferase.
Bashtrykov P; Rajaram N; Jeltsch A
Methods Mol Biol; 2023; 2577():177-188. PubMed ID: 36173573
[TBL] [Abstract][Full Text] [Related]
5. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.
Nuñez JK; Chen J; Pommier GC; Cogan JZ; Replogle JM; Adriaens C; Ramadoss GN; Shi Q; Hung KL; Samelson AJ; Pogson AN; Kim JYS; Chung A; Leonetti MD; Chang HY; Kampmann M; Bernstein BE; Hovestadt V; Gilbert LA; Weissman JS
Cell; 2021 Apr; 184(9):2503-2519.e17. PubMed ID: 33838111
[TBL] [Abstract][Full Text] [Related]
7. Allele-Specific Epigenome Editing.
Bashtrykov P; Jeltsch A
Methods Mol Biol; 2018; 1767():137-146. PubMed ID: 29524132
[TBL] [Abstract][Full Text] [Related]
8. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
[TBL] [Abstract][Full Text] [Related]
9. In vivo epigenome editing and transcriptional modulation using CRISPR technology.
Lau CH; Suh Y
Transgenic Res; 2018 Dec; 27(6):489-509. PubMed ID: 30284145
[TBL] [Abstract][Full Text] [Related]
10. A modular dCas9-SunTag DNMT3A epigenome editing system overcomes pervasive off-target activity of direct fusion dCas9-DNMT3A constructs.
Pflueger C; Tan D; Swain T; Nguyen T; Pflueger J; Nefzger C; Polo JM; Ford E; Lister R
Genome Res; 2018 Aug; 28(8):1193-1206. PubMed ID: 29907613
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review.
Syding LA; Nickl P; Kasparek P; Sedlacek R
Cells; 2020 Apr; 9(4):. PubMed ID: 32316223
[TBL] [Abstract][Full Text] [Related]
12. Epigenome editing strategies for the functional annotation of CTCF insulators.
Tarjan DR; Flavahan WA; Bernstein BE
Nat Commun; 2019 Sep; 10(1):4258. PubMed ID: 31534142
[TBL] [Abstract][Full Text] [Related]
13. Transgenic mice for in vivo epigenome editing with CRISPR-based systems.
Gemberling MP; Siklenka K; Rodriguez E; Tonn-Eisinger KR; Barrera A; Liu F; Kantor A; Li L; Cigliola V; Hazlett MF; Williams CA; Bartelt LC; Madigan VJ; Bodle JC; Daniels H; Rouse DC; Hilton IB; Asokan A; Ciofani M; Poss KD; Reddy TE; West AE; Gersbach CA
Nat Methods; 2021 Aug; 18(8):965-974. PubMed ID: 34341582
[TBL] [Abstract][Full Text] [Related]
14. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA
Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517
[TBL] [Abstract][Full Text] [Related]
15. Epigenome engineering: new technologies for precision medicine.
Sgro A; Blancafort P
Nucleic Acids Res; 2020 Dec; 48(22):12453-12482. PubMed ID: 33196851
[TBL] [Abstract][Full Text] [Related]
16. DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A.
Huang YH; Su J; Lei Y; Brunetti L; Gundry MC; Zhang X; Jeong M; Li W; Goodell MA
Genome Biol; 2017 Sep; 18(1):176. PubMed ID: 28923089
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
18. Reversing Mechanoinductive DSP Expression by CRISPR/dCas9-mediated Epigenome Editing.
Qu J; Zhu L; Zhou Z; Chen P; Liu S; Locy ML; Thannickal VJ; Zhou Y
Am J Respir Crit Care Med; 2018 Sep; 198(5):599-609. PubMed ID: 29924937
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors.
Wang H; Guo R; Du Z; Bai L; Li L; Cui J; Li W; Hoffman AR; Hu JF
Mol Ther Nucleic Acids; 2018 Jun; 11():23-33. PubMed ID: 29858058
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas mediated epigenome editing for cancer therapy.
Ansari I; Chaturvedi A; Chitkara D; Singh S
Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
